Olix Pharmaceuticals Confirms Safety and Tolerability of Hair Loss Drug in Australian Phase 1 Study

Olix Pharmaceuticals has announced the completion of the Australian Phase 1 clinical trial for OLX72021, a drug aimed at treating androgenetic alopecia, commonly known as male pattern baldness. The trial, which involved 25 healthy adult men, was conducted across three sites in Australia and focused on evaluating the drug's safety, tolerability, pharmacokinetic properties, and its effects on sexual function.

The study employed a single ascending dose (SAD) design, with participants divided into five cohorts. Each cohort consisted of six patients, four of whom received OLX72021, while the remaining two were given a placebo. The primary endpoints of the study included monitoring the incidence and severity of adverse events, changes in physical examination findings, vital signs, electrocardiogram (ECG) results, clinical laboratory tests, and local tolerability at the injection site.

Participants were administered a single intradermal injection of OLX72021 or placebo in six balding areas of the scalp and were followed for 56 days. Observations were conducted on days 7, 14, 28, and 56. The clinical results revealed no serious adverse events related to OLX72021 treatment, with the incidence of adverse events not increasing with the dose. Any adverse events that did occur were deemed to have a low or no causal relationship to the drug.

No clinically significant adverse events were observed in electrocardiograms, vital signs, or clinical laboratory tests. Notably, the two patients who exhibited abnormalities during physical examinations were part of the placebo group.

Olix Pharmaceuticals plans to utilize the findings from this study to guide the strategy for subsequent clinical trials. The company highlighted that OLX72021 is the first RNA-based hair loss treatment to demonstrate safety in clinical trials, marking a significant milestone in the development of treatments for androgenetic alopecia.